What is Visiox Pharma?
Visiox Pharma is a privately funded biopharmaceutical company dedicated to the development and commercialization of ophthalmic therapeutic candidates. The company aims to address highly prevalent diseases within the eye care market that currently lack effective treatment options. Visiox Pharma emphasizes a disruptive and revolutionary approach, striving to maximize patient and physician satisfaction through collaboration with eye care professionals and an agile business model.
How much funding has Visiox Pharma raised?
Visiox Pharma has raised a total of $7M across 1 funding round:
Angel/Seed
$7M
Angel/Seed (2022): $7M with participation from Founding Partners
Key Investors in Visiox Pharma
Founding Partners
Founding Partners, an early-stage investor, has provided seed funding to Visiox Pharma, indicating a focus on supporting nascent biopharmaceutical ventures.
What's next for Visiox Pharma?
The recent major strategic investment signals a pivotal growth phase for Visiox Pharma, likely enabling the company to accelerate its development pipeline and advance its therapeutic candidates toward clinical trials and potential commercialization. This enterprise-level funding suggests confidence from investors in Visiox Pharma's strategy to innovate within the ophthalmic therapeutic landscape and capture significant market share. The company is poised to leverage this capital for research, development, and strategic partnerships to achieve its mission of revolutionizing eye care.
See full Visiox Pharma company page
